Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta
NCT07062588Phase 2Recruiting
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of AGA2115 in osteogenesis imperfecta (OI) (4 arms), sponsored by Angitia Biopharmaceuticals. Primary endpoint: Bone Mineral Density at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
AGA2115
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT07062588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062588.